Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: Critical assessment of a practical dosing regimen

Timothy M. Fan, Barbara E. Kitchell, Ravinder S. Dhaliwal, Pamela D. Jones, John G. Hintermeister, Biman C. Paria

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty cats with spontaneously arising tumors received oral lomustine at a dose range of 32 to 59 mg/m2 every 21 days. Due to biohazard concerns associated with lomustine capsule reformulation, a standardized 1O-mg capsule dosage was used for all cats regardless of body weight. Severe hematological toxicity was infrequent, with the incidence of either grade III or IV neutropenia and thrombocytopenia being 4.1 % and 1.0%, respectively. Cats receiving higher cumulative doses of lomustine trended toward a greater likelihood for progressive neutropenia (P=0.07). Two cats with lymphoma, two cats with fibrosarcoma, and one cat with multiple myeloma achieved a measurable partial response to lomustine therapy. Cats treated with higher dosages of lomustine trended toward statistically significant higher response rates (P=0.07).

Original languageEnglish (US)
Pages (from-to)357-363
Number of pages7
JournalJournal of the American Animal Hospital Association
Volume38
Issue number4
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Small Animals

Fingerprint

Dive into the research topics of 'Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: Critical assessment of a practical dosing regimen'. Together they form a unique fingerprint.

Cite this